Table 1 Structures and in vitro activities of pepstatin and analogues.

From: Esterase mutation is a mechanism of resistance to antimalarial compounds

Compound

Structure

Potency* (ÎĽM)

Pepstatin (P)

Iva-Val-Val-Sta-Ala-Sta-OH

none at 40

Acetyl pepstatin

Ac-Val-Val-Sta-Ala-Sta-OH

none at 20

Pepstatin-Penetratin

Pepstatin-RQIKIWFQNRRMKWKK-OH

none at 1

Pepstatin n-butyl amide

Pepstatin-CO-NH-(CH2)3CH3

none at 20

Pepstatin methyl ester (PME)

Pepstatin-COO-CH3

5.12±0.15

Pepstatin ethyl ester (PEE)

Pepstatin-COO-CH2-CH3

0.730±0.012

Pepstatin 3-methyl-1-butyl ester (PMBE)

Pepstatin-COO-(CH2)2CH-(CH3)2

0.071±0.010

Pepstatin n-butyl ester (PBE) prep 1

Pepstatin-COO-(CH2)3-CH3

0.083±0.006

Pepstatin n-butyl ester (PBE) prep 2

Pepstatin-COO-(CH2)3-CH3

0.092±0.006

Pepstatin n-hexyl ester (PHE) prep 1

Pepstatin-COO-(CH2)5-CH3

0.019±0.003

Pepstatin n-hexyl ester (PHE) prep 2

Pepstatin-COO-(CH2)5-CH3

0.026±0.003

  1. EC50s of pepstatin and analogues against 3D7 asexual stage parasites measured using a flow cytometry-based assay. Inhibition data were fit to a sigmoidal concentration-response curve using the least squares fit function and without outlier elimination±are standard errors. n=2–5 (biological replicates performed in triplicate for each experiment).
  2. *Potency—where appropriate, potency is presented as EC50. For inactive compounds, inhibition at highest concentration is presented.